“Organ Transplant Immunosuppressive Markets”, which is available at http://www.reportbuyer.com/
Authors of the report note that improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts.
The report shows that rejection remains the major barrier to long-term graft survival in patients. Organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient's immune responses to the foreign organ. Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used.
The report is focused on immunosuppressants utilised in solid organ transplantation. It provides an in-depth look into the trends that have shaped today's use of transplant immunosuppression regimens, and details the current and future global market.
Included in this report:
- Detailed statistics on Transplant Need, Organ Transplant Procedures, Costs, Patient Waiting Lists, and Patient Survival Rates
- Immunosupressive Current Market and Forecasts
- Breakouts of Immunosuppressive Drugs by Drug Type and by Organ Transplanted
- Regional Breakout of Immunosuppressive Sales (US, Europe, Asia/Pacific, Rest of World)
- Market Share of Immunosuppressive Market
- Review of Current Products and New Products in Development
- Profiles of Immunosuppressive Market Competitors
“Organ Transplant Immunosuppressive Markets” is available from Report Buyer. For more information go to: http://www.reportbuyer.com/
Report Buyer product ID: KAL00109
